In cases with ROS1 fusions, ROS1 inhibitors (e.g., crizotinib) may be considered, as clinical studies have shown some efficacy in ROS1 fusion-positive IMT. The gene discussed is ROS1; the disease is inflammatory myofibroblastic tumor.